Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given voluntary written consent and are willing to follow the trial's requirements
• People aged 18 or older
• People with an expected survival time of at least 3 months
• People with a good general level of daily functioning, rated 0 or 1 on a standard cancer performance scale (meaning fully active or able to carry out light work)
• People with advanced non-small cell lung cancer confirmed by a tissue or cell sample analysis
• People who have completed 4 to 6 cycles of first-line chemotherapy combined with immunotherapy, where a PET-CT scan afterwards showed no overall worsening of disease, with no more than 5 remaining lesions that did not fully clear up, spread across no more than 3 organs
• People whose remaining lesions have been assessed by a radiation specialist as safe to treat with radiation therapy
• People who are physically able to tolerate the radiation therapy process, such as lying still in the required position
• People who have at least one remaining lesion that is measurable by standard criteria (RECIST v1.1)
• People who are able to provide stored or fresh tumour tissue samples (if tissue cannot be provided, the trial investigator may still consider enrolment based on other criteria)
• People whose side effects from previous cancer treatments have settled to a mild level (Grade 1 or lower), with some specific exceptions allowed (such as hair loss, fatigue, skin changes, stable thyroid issues on hormone replacement, or mild nerve-related symptoms)
• People whose blood test results at screening meet specific thresholds for white blood cells, platelets, haemoglobin, kidney function, liver enzymes, bilirubin, and thyroid hormone levels (confirm specific values with the trial site)

Who may not be able to join:

• People whose tumour tissue shows small cell lung cancer or a mixed small cell/non-small cell type
• People whose tumour genetic testing shows certain gene changes (such as EGFR mutations or ALK fusions) that would normally be treated with targeted therapy as a first-line treatment
• People who currently have brain metastases causing symptoms
• People whose cancer has spread to the lining around the brain or spinal cord
• People with an active or suspected autoimmune disease, with some exceptions such as vitiligo, type 1 diabetes, or stable thyroid conditions managed with hormone replacement
• People with active tuberculosis, or a history of active tuberculosis within the past year; people with tuberculosis more than one year ago may also be excluded unless documented effective treatment can be confirmed
• People who need to take immunosuppressive medications or corticosteroids at immune-suppressing doses
• People who are pregnant or breastfeeding
• People with symptomatic interstitial lung disease (scarring or inflammation of the lungs) that could interfere with monitoring for drug-related lung side effects
• People who test positive for HIV antibodies, have active hepatitis B, or have active hepatitis C infection
• People with a history of serious neurological or psychiatric conditions, including but not limited to dementia, depression, seizures, or bipolar disorder
• People who have taken another investigational drug or received an experimental treatment within the 4 weeks before joining the trial
• People who have used any Chinese herbal medicines with anti-cancer properties within 2 weeks before starting the study treatment
• People with a history of another cancer, unless it was fully in remission for at least 2 years before enrolment and no further treatment is needed or expected (some skin and in situ cancers may be excepted — confirm with the trial site)
• People with a history of serious heart or stroke-related conditions, such as moderate-to-severe heart failure, a heart attack or unstable chest pain in the past 6 months, or a stroke or related event in the past 6 months
• People who have had a serious blood clot event requiring treatment within the 6 months before screening, such as deep vein thrombosis, arterial clots, or pulmonary embolism
• People who have received a live vaccine, or plan to receive one, within 28 days before joining the trial
• People whom the trial investigator considers unsuitable for participation for any other medical or personal reason

Important: Always verify eligibility with the trial site directly before applying.